Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01579084 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability of AGN-199201 in Patients With Erythema Associated With Rosacea
A Phase 1 study of Rosacea and Erythema, sponsored by Allergan.
- Completed
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
- 1
- Study location
NCT01579084 is a Phase 1 study of Rosacea and Erythema that has completed, run by Allergan. The registered enrollment target is 64 participants, below the 240-participant average among 23 other Rosacea trials with a reported enrollment target (73% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01579084, a Phase 1 study of Rosacea and Erythema, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate the safety and tolerability of AGN-199201 for the treatment of erythema associated with rosacea.
Interventions
- DRUG AGN-199201 Formulation A
- DRUG AGN-199201 Formulation B
- DRUG AGN-199201 Formulation C
- DRUG AGN-199201 Vehicle
Study Locations (1)
Texas
- - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2012-04 |
| Est. Completion | 2012-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01579084
The ClinicalTrials.gov registry entry for NCT01579084 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 240-participant average among 23 other Rosacea trials with a reported enrollment target (73% lower). The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Rosacea appearing as the primary indexed condition, and to 4 interventions - of which AGN-199201 Formulation A is the first listed.
NCT01579084 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT01579084 about?
NCT01579084 is a clinical study titled "Safety and Tolerability of AGN-199201 in Patients With Erythema Associated With Rosacea". This study will evaluate the safety and tolerability of AGN-199201 for the treatment of erythema associated with rosacea.
What is the current status of trial NCT01579084?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2012-04. Estimated completion is 2012-06.
What conditions does trial NCT01579084 study?
This clinical trial studies the following conditions: Rosacea, Erythema.
What interventions are being tested in trial NCT01579084?
The interventions under investigation include: AGN-199201 Formulation A (DRUG), AGN-199201 Formulation B (DRUG), AGN-199201 Formulation C (DRUG), AGN-199201 Vehicle (DRUG).
Who is sponsoring clinical trial NCT01579084?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01579084 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rosacea
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Impact of DFD-29 on Microbial Flora of Healthy, Adult Human Subjects When Administered Over 16 Weeks
COMPLETED · Phase 1
-
Topical Agent for Treatment of Red Skin
COMPLETED · Phase 1
-
Timolol for the Treatment of Acne and Rosacea
COMPLETED · Phase 1
-
Evaluation of the Inhibitory Effects of Topical Ivermectin on Markers of Rosacea Specific Inflammation.
COMPLETED · Phase 1
-
A Therapeutic Equivalence Study of Two Metronidazole 1%Topical Gel Treatments for Patients With Rosacea
COMPLETED · Phase 1
-
Effects of Oral Supplement Containing L-Histidine and Antioxidants on the Skin Barrier Function and Systemic Inflammation in Rosacea
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.